1. MAPK/ERK Pathway
  2. JNK

D-JNKI-1 (Synonyms: AM-111; XG-102)

Cat. No.: HY-P0069
Handling Instructions

D-JNKI-1 is a specific inhibitor of JNK, and strongly interferes with JNK activation.

For research use only. We do not sell to patients.
D-JNKI-1 Chemical Structure

D-JNKI-1 Chemical Structure

CAS No. :

Size Price Stock Quantity
1 mg $150 In-stock
5 mg $300 In-stock
10 mg $450 In-stock
50 mg $1150 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • References

Description

D-JNKI-1 is a specific inhibitor of JNK, and strongly interferes with JNK activation.

In Vitro

D-JNKI-1 (1 μM-1 mM) treatment prevents apoptosis and loss of neomycin-exposed hair cells[1].

In Vivo

D-JNKI-1 (10 μM) prevents nearly all hair cell death and permanent hearing loss induced by neomycin ototoxicity in the scala tympani of the guinea pig cochlea. Local delivery of D-JNKI-1 also prevents acoustic trauma-induced permanent hearing loss in a dose-dependent manner[1]. D-JNKI-1 (0.3 mg/kg, i.p.) reverses these pathological events in the brain mitochondria of the rat and almost completely abolishes cytochrome c release and PARP cleavage[2]. D-JNKI-1 (1 μg/kg, s.c.) results in a significant decrease in the disease activity index, and reduces the expression of CD4+ and CD8+ cells in mice[3].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02809118 Auris Medical, Inc. Hearing Loss, Idiopathic Sudden Sensorineural June 2016 Phase 3
NCT02561091 Auris Medical AG|Auris Medical, Inc. Hearing Loss November 2015 Phase 3
NCT00802425 Auris Medical AG|Auris Medical, Inc. Hearing Loss December 2008 Phase 2
NCT02809118 Auris Medical, Inc. Hearing Loss, Idiopathic Sudden Sensorineural June 2016 Phase 3
NCT02561091 Auris Medical AG|Auris Medical, Inc. Hearing Loss November 2015 Phase 3
NCT00802425 Auris Medical AG|Auris Medical, Inc. Hearing Loss December 2008 Phase 2
NCT02235272 Xigen SA Inflammation|Pain|Cataract September 2014 Phase 3
NCT01570205 Xigen SA Inflammation July 2011 Phase 1
NCT02508337 Xigen SA Inflammation|Pain|Cataract July 2015 Phase 3
View MoreCollapse
References
Animal Administration
[3]

D-JNKI-1 is dissolved in a 0.9% sodium chloride solution.

D-JNKI-1 is dissolved in a 0.9% sodium chloride solution for subcutaneous application. Each group (the 1.0% DSS group and the 1.5% DSS group) is randomly subdivided into an intervention group (n = 15) and a control group (n = 15). The mice in the intervention group receive three subcutaneous nuchal administrations of 1 μg/kg D-JNKI-1 on days 2, 12, and 22. The mice in the control group receive physiological saline subcutaneously as a negative control at the same time points in a comparable stress situation. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

15.03

Formula

CH₃

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

H2O

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
D-JNKI-1
Cat. No.:
HY-P0069
Quantity: